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Abstract
Background: Cathepsin-D (CatD), owing to its dual role as a proteolytic enzyme and as a ligand, has been implicated in cancer
progression. The role of CatD in pancreatic ductal adenocarcinoma is unknown.
Methods: CatD expression quantified by immunohistochemistry of tumor-tissue microarrays of 403 resected pancreatic can-
cer patients from the ESPAC-Tplus trial, a translational study within the ESPAC (European Study Group for Pancreatic Cancer)
trials, was dichotomously distributed to low and high H scores (cut off 22.35) for survival and multivariable analysis. The vali-
dation cohort (n¼69) was recruited based on the hazard ratio of CatD from ESPAC-Tplus. 5-fluorouracil-, and gemcitabine-
resistant pancreatic cancer cell lines were employed for mechanistic experiments. All statistical tests were two-sided.
Results: Median overall survival was 23.75 months and median overall survival for patients with high CatD expression was
21.09 (95% confidence interval [CI] ¼ 17.31 to 24.80) months vs 27.20 (95% CI ¼ 23.75 to 31.90) months for low CatD expression
(v2LR, 1DF ¼ 4.00; P¼ .04). Multivariable analysis revealed CatD expression as a predictive marker in gemcitabine-treated (z stat
¼ 2.33; P¼ .02) but not in 5-fluorouracil-treated (z stat ¼ 0.21; P¼ .82) patients. An independent validation cohort confirmed
CatD as a negative predictive marker for survival (v2LR, 1DF ¼ 6.80; P¼ .009) and as an independent predictive marker in
gemcitabine-treated patients with a hazard ratio of 3.38 (95% CI ¼ 1.36 to 8.38, P ¼ .008). Overexpression of CatD was associ-
ated with a concomitant suppression of the acid sphingomyelinase, and silencing of CatD resulted in upregulation of acid
sphingomyelinase with rescue of gemcitabine resistance.
Conclusions: Adjuvant gemcitabine is less effective in pancreatic ductal adenocarcinoma with high CatD expression, and
thus CatD could serve as a marker for biomarker-driven therapy.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most ag-
gressive malignancies and burdened with a 5-year survival rate
of only 6% (1,2). Multiple factors are known to contribute to this
dismal prognosis, with delayed diagnosis and resistance to
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chemotherapy or radiation therapy most prominent (3,4). The
use of adjuvant chemotherapy with either 5-fluorouracil-folinic
acid (5FU/FA) or gemcitabine increases estimated 5-year sur-
vival to around 17% (4,5). Use of gemcitabine did not show a sur-
vival benefit over 5FU/FA, although gemcitabine has been the
treatment of choice because of its better safety profile compared
to 5FU/FA (4). Even though insights into the molecular pathol-
ogy of cancer can create opportunities for the development of
therapies with substantial clinical benefit (6), for pancreatic
cancer, such options are currently unavailable (5,7). Biomarker-
driven treatment strategies are urgently needed for PDAC, but
their successful development requires studies according to
Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK) guidelines to reduce bias (6). To identify a rel-
evant biomarker, we used archival material from randomized,
controlled trials, European Study Group for Pancreatic Cancer
(ESPAC-1 [8] and 3 [4]), balanced for treatment arms, and strati-
fied for cancer stage in resected pancreatic cancer patients.
As a candidate biomarker, we chose the lysosomal aspartic
protease cathepsin-D (CatD) (9). CatD is overexpressed and
hypersecreted in some epithelial cancers (10). In addition to its
ubiquitous role in lysosomes, two biologic activities of the se-
creted precursor have been demonstrated in vitro: mitogenic ac-
tivity and proteolytic activity for various substrates including
proteoglycans and basement membranes in an acidic milieu.
Both the growth-promoting activity and its extracellular proteo-
lytic activity suggest that CatD may be of prognostic relevance
in pancreatic cancer (9,11,12). Correlation of CatD expression
with cancer progression and patient survival has been investi-
gated in a number of solid tumors (11–14), with conflicting out-
comes especially in breast cancer (15). Here, we determined
whether tumor cell CatD expression predicts overall survival
and treatment-related survival in patients receiving adjuvant
gemcitabine or 5FU/FA in the ESPAC-Tplus trial. We validated
our findings in an independent, prospectively recruited cohort
and used tumor cell culture studies to identify the underlying
cellular mechanisms.
Methods
Study Design
The translational ESPAC-Tplus studies received ethical commit-
tee approval for characterization of tumor markers for chemo-
therapy from the Liverpool (Adult) Research Ethics Committee
(07/H1005/87). Use of good clinical practice standard operating
procedures (16) ensured a full audit trail and prevented access
to outcome data by pathologists and laboratory researchers.
After resection for PDAC, patients in the ESPAC-3 study were
randomly assigned to receive either 5FU/FA or gemcitabine.
ESPAC-3 was analyzed on an intention-to-treat basis, but in the
ESPAC-Tplus study, patients in the treatment arms were se-
lected for inclusion only if treatment was actually received. This
study was conducted and reported in accordance with the
REMARK criteria (17–19).
For independent validation, we analyzed 69 resected
patients with PDAC who were receiving adjuvant gemcitabine
treatment and were recruited at the University of Munich. All
the patients in the validation provided informed consent.
Sample size was calculated based on the hazard ratio (HR) in
the standard Cox proportional hazard model of CatD expression
calculated from the multivariable analysis in the gemcitabine-
treated arm (20). Details of tissue microarray manufacturing are
described in Supplementary Materials and Methods (available
online).
Immunohistochemistry
Immunohistochemistry of 2 lm sections of the tissue microar-
rays core for CatD (goat polyclonal CatD, G20, Santacruz, 1:100
diluted in phosphate-buffered saline) was performed as de-
scribed previously (21,22). The methodology adopted for scoring
and H score calculations are described in Supplementary
Materials and Methods (available online).
Statistical Analysis
The first null hypothesis was that CatD levels do not predict
survival in patients receiving adjuvant chemotherapy. All anal-
yses were carried out using R (R statistical computing environ-
ment) 3.4.4 GUI 1.70 El Capitan build (7507) and R studio 1.1.442
on an intention-to-treat basis, retaining patients in their ran-
domly assigned treatment groups and including noneligible
patients. Features of statistical analyses are described in
Supplementary Materials and Methods (available online). A
two-sided statistical significance (P< .05) was used throughout.
Cell Lines and In Vitro Experiments
The pancreatic adenocarcinoma cell lines PaTU-8988T, BxPC3,
and L3.6pl were used for in vitro experiments. L3.6pl cells were
received from Prof Christine J. Bruns and maintained as de-
scribed previously (23). The detailed methodology for in vitro
experiments is described in the Supplementary Materials and
Methods (available online).
Results
Patients and Tissue Samples
For the identification study, tissue microarrays of 403 patients
from the ESPAC-1 and ESPAC-3 trials were selected representing
202 gemcitabine-treated and 201 5FU/FA-treated patients
(Figure 1A). In the final analysis, 362 patients and 1789 tissue
microarray cores were included. The demographics, surgery,
and pathology reports of these patients are shown in Table 1.
Cathepsin D Labeling
The CatD antibody used for this study has been characterized
for CatD specificity using immunoblotting, immunofluores-
cence, and immunohistochemistry in human and mouse cell
lines as well as human and mouse PDAC tissues
(Supplementary Figure 1, A–F, available online). Pancreatic tis-
sue from CatD knockout mice generated previously (24) served
as a control. CatD showed persistent and differential expression
in PDAC specimens (Supplementary Figure 1G, available online).
In 362 patients (89.10%), the overall median H score was 58.45
for ductal tumor cells, ranging from 0 to 237 (Figure 1B). To ex-
clude direct interactions between CatD and chemotherapy, we
performed a subpopulation treatment effect pattern plot analy-
sis. This showed a trend toward higher overall survival in
patients with lower CatD values, especially in gemcitabine-
treated patients (Supplementary Figure 2A, available online).
Further, subpopulations with high CatD expression, considering
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5F-treated patients as baseline, did not reveal actual differences
in risk for median survival in various CatD expression sub-
groups between 5FU/FA- and gemcitabine-treatment groups
(P¼ .09; Figure 1C). Having excluded biomarker-treatment inter-
actions, we dichotomized the patients based on CatD expres-
sion as low and high CatD-expressing patients. Patients
Figure 1. Association of CatD expression with overall survival and progression-free survival in resected PDAC patients (ESPAC cohort). A) CONSORT diagram. B)
Relative frequency distribution and rug plot of CatD H-score in 362 patients. C) The plot shows the actual differences in risk at median survival in various CatD expres-
sion subgroups between the 5FU/FA- and gemcitabine-treatment groups (solid line) with a 95% CI (dashed lines). Solid red horizontal line indicates overall treatment
effect, and dotted vertical lines indicate the cutoff for the dichotomization. P values are from interaction test with bootstrapping. D) Survival curves dichotomized by
CatD expression levels (high ¼ median H score > 22.35; low ¼ mean H score  22.35). E) Progression-free survival dichotomized by CatD expression levels. All groups
and the number of at-risk individuals are shown at the bottom of graph. All statistical tests were log-rank analyses using two-sided v2 tests. P< .05 considered statisti-
cally significant. 5FU/FA ¼ 5-fluorouracil-folinic acid; CatD ¼ cathepsin D; CI ¼ confidence level; CONSORT = Consolidated Standards of Reporting Trials; ESPAC ¼
European Study Group for Pancreatic Cancer; FFPE ¼ formalin-fixed paraffin-embedded; m(st) ¼ median survival time; m(pfst) ¼ median progression-free survival
time; PDAC ¼ pancreatic ductal adenocarcinoma; TMA ¼ tissue microarray.
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expressing CatD in tumor cells were subdivided using Cutoff
finder (25), setting an overall median H-score of 22.35 as a
threshold, and expression higher than threshold was regarded
as high expression of CatD (Supplementary Figure 3, A and B,
available online). In CatD-expressing patients, the event rate
was 79.6%, with 228 deaths displaying high and 60 (20.4%) dis-
playing low expression of CatD. In the gemcitabine-treatment
group, we observed 152 (80.85%) deaths of which 137 (90.1%) dis-
played high CatD expression. In the 5FU/FA-treatment group,
there were 136 (78.16%) deaths, of which 91 (66.9%) showed high
Table 1. Demographics, surgery, and pathology features of the patients scored for CatD*
Demographics Total No. (%) (n ¼ 362)
Chemotherapy
5FU/FA (%) (n ¼ 174) Gemcitabine (%) (n ¼ 188)
Age, median (IQR), y 64 (32–83) 63 (38–83) 64 (32–82)
Sex
Female 153 (42.30) 75 (43.10) 78 (41.50)
Male 209 (57.70) 99 (56.90) 110 (58.50)
Baseline performance score
0 121 (33.40) 61 (35.10) 60 (31.90)
1 195 (53.90) 90 (51.70) 105 (55.90)
2 46 (12.70) 23 (13.20) 23 (12.20)
Diabetic, No. 348 166 182
No 274 (78.70) 131 (78.90) 143 (78.60)
IDDM 43 (12.40) 20 (12.00) 23 (12.60)
NIDDM 31 (8.90) 15 (9.00) 16 (8.80)
Smoking, No. 326 158 168
Never 143 (43.90) 72 (45.60) 71 (42.30)
Past 127 (39.00) 60 (38.00) 67 (39.90)
Present 56 (17.20) 26 (16.50) 30 (17.90)
Postoperative CA19-9, No.
Median (IQR), kU/L
265 131 134
28 (0–27 016) 33 (0–4258) 24.5 (0–27 016)
Surgery to random assignment, median (IQR), d 49 (4–92) 49 (4–88) 49 (7–92)
Surgery, No. 354 170 184
Whipple resection 185 (52.30) 92 (54.10) 93 (50.50)
Pylorus preserving 139 (39.30) 63 (37.10) 76 (41.30)
Distal pancreatectomy 19 (5.40) 8 (4.70) 11 (6.00)
Total pancreatectomy 11 (3.10) 7 (4.10) 4 (2.20)
Extent of resection, No. 346 166 180
Standard 262 (75.70) 135 (81.30) 127 (70.60)
Radical 47 (13.60) 20 (12.00) 27 (15.00)
Extended radical 37 (10.70) 11 (6.60) 26 (14.40)
Maximum tumor diameter, No.
Median (IQR), mm
342 165 177
30 (3–350) 27 (3–350) 30 (3–105)
Tumor grade, No. 355 171 184
Well 27 (7.60) 12 (7.00) 15 (8.20)
Moderate 229 (64.50) 108 (63.20) 121 (65.80)
Poor 99 (27.90) 51 (29.80) 48 (26.10)
Lymph node invasion
Negative 79 (21.80) 38 (21.80) 41 (21.80)
Positive 283 (78.20) 136 (78.20) 147 (78.20)
Resection margin
Negative 202 (55.80) 90 (51.70) 112 (59.60)
Positive 160 (44.20) 84 (48.30) 76 (40.40)
Local invasion, No. 352 170 182
No 189 (53.70) 92 (54.10) 97 (53.30)
Yes 163 (46.30) 78 (45.90) 85 (46.70)
Tumor stage, No. 358 173 185
I 23 (6.40) 12 (6.90) 11 (5.90)
II 98 (27.40) 47 (27.20) 51 (27.60)
III 228 (63.70) 108 (62.40) 120 (64.90)
IV 9 (2.50) 6 (3.50) 3 (1.60)
CatD expression
Low 80 (22.10) 59 (34.00) 21 (11.20)
High 282 (77.90) 115 (66.00) 167 (88.80)
*5FU/FA ¼ 5-fluorouracil-folinic acid; CatD ¼ cathepsin D; CI ¼ confidence interval; IDDM ¼ insulin-dependent diabetes mellitus; IQR ¼ interquartile range; NIDDM ¼
noninsulin-dependent diabetes mellitus.
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CatD expression. Contingency testing of CatD levels with clini-
cal and tumor characteristics (Supplementary Table 1, available
online) did not reveal any statistically significant associations.
Overall Survival Analysis
Median overall survival for patients with CatD expression was
23.75 (95% confidence interval [CI] ¼ 20.63 to 26.11) months.
Median overall survival of patients with low CatD expression
was 27.20 (95% CI ¼ 23.75 to 31.24) months compared to that of
high CatD expression with 21.09 (95% CI ¼ 17.31 to 24.80)
months and a hazard ratio of 1.33 was calculated (95% CI ¼ 1.02
to 1.73, v2 ¼ 4.00; P¼ .04) (Figure 1D). To assess the influence of
CatD expression on treatment, we performed LIFETEST analysis
(Supplementary Figure 4A, available online). Median overall sur-
vival for the gemcitabine-treated patients was 23.78 (95% CI ¼
19.25 to 26.34) months compared to 22.60 (95% CI ¼ 18.43 to
27.30) months for patients treated with 5FU/FA. Median survival
in patients treated with 5FU/FA with high or low CatD expres-
sion was 21.45 (95% CI ¼ 15.90 to 27.49) and 25.23 (95% CI ¼ 17.45
to 30.39) months, respectively (v2LR, 1DF ¼ 1.25, P¼ .26)
(Supplementary Figure 4B, available online). Importantly, me-
dian survival for the patients treated with gemcitabine with low
CatD expression was 31.24 (95% CI ¼ 24.11 to 51.31) months
compared to 20.97 (95% CI ¼ 16.68 to 25.13) months in those
with high CatD expression, with a hazard ratio of 1.66 (95% CI ¼
1.06 to 2.58, v2LR, 1DF ¼ 3.60, P¼ .05) (Supplementary Figure 4C,
available online). Survival between the two treatment regimens
did not differ with respect to CatD expression (Supplementary
Figure 4, D and E, available online).
Median progression-free survival for patients with CatD ex-
pression was 12.74 (95% CI = 11.63 to 14.19) months. Median
progression-free survival of patients with low CatD expression
was 16.24 (95% CI ¼ 11.92 to 20.23) months compared to that of
high CatD expression with 12.22 (95% CI ¼ 10.71 to 13.30)
months, with a hazard ratio of 1.21 (95% CI ¼ 0.93 to 1.53, v2 ¼
2.00, P¼ .16) (Figure 1E). Progression-free survival between the
two treatment arms did not differ by differential CatD expres-
sion (Supplementary Figure 5, available online). Pairwise com-
parisons of all variations of CatD level and treatment arms did
not show any association with overall survival as well as pro-
gression-free survival (Supplementary Table 1, available
online).
In performing univariate analysis with overall survival as
the endpoint, we observed significant associations with inde-
pendent variables such as local invasion, lymph node invasion,
postoperative CA19.9, resection margin, and tumor stage. CatD
expression showed a statistically significant correlation with
patients’ survival (Table 2). Progression-free survival did not
show any significant association (Supplementary Table 3, avail-
able online).
Multivariable Analysis
A model for multivariable analysis based on 318 patients (255
deaths) identified lymph node invasion, local invasion, resec-
tion margin, smoking status, and tumor cell CatD expression as
independent survival factors. Cox proportional hazard model
for overall survival revealed statistical significance for CatD ex-
pression in the gemcitabine-treatment arm, with a hazard ratio
of 2.04 (95% CI ¼ 1.10 to 3.76, z statistic ¼ 2.33; P¼ .02, Figure 2A)
but not in patients treated with 5FU/FA, with a hazard ratio of
1.04 (95% CI ¼ 0.71 to 1.52, z statistic ¼ 0.21; P¼ .82; Figure 2B,
Table 3). Comparison of this Cox proportional hazard model (C-
statistics ¼ 0.6260.02) with a model leaving out CatD expres-
sion (C statistics ¼ 0.596 0.02; Supplementary Table 4, available
online) in gemcitabine-treated patients showed statistically sig-
nificant improvement in the stated model after the addition of
CatD expression (P¼ .01). Multivariable analysis with progres-
sion-free survival factors mirrored the same trends
(Supplementary Figure 4C and Supplementary Table 5, available
online).
Because the multivariable analysis considers only complete
cases, we processed our data, barring postoperative CA 19-9 and
excluding all units for which any of the inputs were missing.
Demographics of complete cases are listed in Supplementary
Table 6 (available online). Median overall survival for patients
with CatD expression was 24.11 (95% CI ¼ 20.63.0 to 27.30)
months. Median overall survival of patients with low CatD ex-
pression was 29.60 (95% CI ¼ 23.58 to 41.85) months compared
to that of high CatD expression with 21.45 (95% CI ¼ 17.80 to
25.89) months, and a hazard ratio of 1.44 was calculated (95% CI
¼ 0.98 to 1.44, v2¼ 4.80; P¼ .02; Supplementary Table 7, available
online). Cox proportional hazard model for overall survival
revealed statistical significance for CatD expression in the gem-
citabine-treated complete cases with a hazard ratio of 2.24 (95%
CI ¼ 1.14 to 4.40, z statistic ¼ 2.35; P¼ .01, Supplementary Figure
8A, available online) but not in 5FU/FA-treated patients, with a
hazard ratio of 0.92 (95% CI ¼ 0.61 to 1.40, z statistic ¼ 0.34;
P¼ .72, Supplementary Figure 8B and Supplementary Table 7,
available online). Although exclusion of missing data led to loss
of power in the multivariable analysis (n¼ 325 patients, HR for
high CatD ¼ 2.04), we did not observe a significant change in
hazard ratio comparing results from the multivariable analysis
of complete cases (n¼ 287 patients, HR for high CatD ¼ 2.24).
Independent Validation
The prespecified hypothesis for the independent validation co-
hort was based on the Cox proportional hazard model, with a
hazard ratio of 2.04 in the gemcitabine-treated arm from the iden-
tification study. We calculated a sample size of 69 patients aiming
for a b-error of 0.8 and an a-error of less than 0.05 and recruited
69 patients (207 cores) from PDAC patients resected in the
Department of Surgery at the University of Munich and receiving
adjuvant gemcitabine treatment. In total, we analyzed 201 cores
(97.1%) corresponding to 69 patients (Figure 2C). The demo-
graphics of patients are shown in Supplementary Table 8 (avail-
able online). We observed 38 (76.0%) deaths, with 30 (78.9%)
deaths showing high and eight (21.0%) showing low expression of
CatD in the gemcitabine-treatment group. We did not observe
any statistically significant associations on contingency testing of
CatD levels with clinical and tumor characteristics
(Supplementary Table 9, available online).
We were able to compare the ability to predict survival time
of the Cox proportional hazard model excluding smoking status
in the validation cohort. We did not observe any statistical dif-
ference between predicted and observed survival time, depict-
ing robustness of the model (Figure 2D). Median overall survival
of patients was 33.89 (95% CI ¼ 23.96 to 41.16) months. The me-
dian survival for patients with low CatD expression in the vali-
dation cohort was 51.48 (95% CI ¼ 20.97 to 55.34) months vs
30.57 (95% CI ¼ 23.27 to 36.42) months for high CatD expression,
(v2LR, 1DF¼ 6.80; P¼ .009; Figure 2E). The difference between over-
all survival in the identification and validation cohort can be
explained by several factors. First, excellent surgical outcomes
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in a high-volume tertiary-care center per se influence overall
survival. Secondly, the high number of patients completing
their course of adjuvant chemotherapy without dose reduction
or chemotherapy breaks affects overall survival. Thirdly, care-
ful, structured follow-up and early palliative treatment in recur-
rence often followed by second- or third-line palliative systemic
therapy in the setting of clinical trials influenced outcome. All
these factors have individually contributed to improved overall
survival. We did not detect a statistically significant association
between low and high CatD expression and progression-free
survival, with v2LR, 1DF ¼ 0.20; P¼ .61; (Supplementary Figure 9A,
available online). In performing univariate analysis using over-
all survival as the endpoint, we observed, as expected, statisti-
cally significant associations with independent variables such
as tumor grading, tumor stage, vascular invasion, perineural in-
vasion, and CatD expression. Univariate analysis with progres-
sion-free survival as the endpoint did not show a statistically
significant association (Supplementary Table 10, available
online).
Multivariable analysis with sex, lymph node status, local in-
vasion status, and CatD expression revealed CatD expression as
an independent predictive marker in gemcitabine-treated
patients, with a hazard ratio of 3.38 (95% CI ¼ 1.36 to 8.38;
P¼ .008; Figure 2F, Table 3). However, progression-free survival
did not show any association, with a hazard ratio of 1.37 (95%
CI ¼ 0.67 to 2.79; P¼ .37; Supplementary Figure 9B and
Supplementary Table 7, available online). In summary, the vali-
dation cohort confirmed the prognostic value of CatD estab-
lished in the ESPAC cohort, highlighting the fact that patients
with high CatD expression have an impaired response to gemci-
tabine treatment.
Influence of CatD on Gemcitabine Resistance
The confirmation in the validation cohort showed high CatD ex-
pression to be correlated with poor survival in gemcitabine-
treated patients. CatD is known to be activated by ceramide,
and low levels of ceramide are implicated in gemcitabine resis-
tance (26,27). Acid sphingomyelinase (ASMase) is a rate-limiting
enzyme in the conversion of ceramide by breaking down sphin-
gomyelin (28). To study the influence of CatD in driving gemci-
tabine resistance, we analyzed CatD expression in 5FU- and
gemcitabine-resistant cell lines (L3.6pl, BxPC3, and PaTu-8988T).
We detected high CatD expression with a concomitant decrease
in expression of caspase 3 and ASMase in gemcitabine-resistant
cell lines (Figure 3A). 5FU-resistant cell lines did not show a
change in CatD expression with respect to control. We
Table 2. Univariate analysis of overall survival factors*
Characteristics
All patients (n¼362) 5-fluorouracil-folinic acid (n¼ 174) Gemcitabine (n ¼ 188)
HR (95% CI) v2 P HR (95% CI) v2 P HR (95% CI) v2 P
Age 0.99 (0.98 to 1.00) 1.43 .23 0.98 (0.97 to 1.00) 1.33 .25 0.99 (0.97 to 1.01) 0.25 . 62
Sex , No. 362 174 188
Female 1 (Referent) 1 (Referent) 1 (Referent)
Male 0.91 (0.72 to 1.14) 0.68 .41 0.89 (0.63 to 1.25 0.42 .51 0.92 (0.67 to 1.27) 0.23 .63
Smoking, No. 326 158 168
Never 1 (Referent) 1 (Referent) 1 (Referent)
Past 1.15 (0.88 to 1.51) 1.11 .29 1.07 (0.73 to 1.59) 0.32 .70 1.23 (0.85 to 1.80) 3.89 .26
Present 1.34 (0.96 to 1.88) 2.00 .09 1.14 (0.70 to 1.87) 2.00 .59 1.57 (0.99 to 2.50) 2.00 .05
Lymph node invasion, No. 362 174 188
Negative 1 (Referent) 1 (Referent) 1 (Referent)
Positive 2.00 (1.47 to 2.73) 19.42 <.001 2.35 (1.48 to 3.72) 13.26 <.001 1.70 (1.12 to 2.58) 6.21 .01
Resection margin, No. 362 174 188
Negative 1 (Referent) 1 (Referent) 1 (Referent)
Positive 1.56 (1.24 to 1.97) 14.01 <.001 1.74 (1.24 to 2.45) 10.24 .001 1.40 (1.01 to 1.93) 4.18 .04
Local invasion 352 170 182
No 1 (Referent) 1 (Referent) 1 (Referent)
Yes 1.34 (1.06 to 1.69) 5.96 .01 1.39 (0.99 to 1.95) 3.66 .05 1.29 (0.94 to 1.79) 2.49 .11
Tumor stage, No. 358 173 185
I 1 (Referent) 1 (Referent) 1 (Referent)
II 1.67 (0.91 to 3.08) 12.65 .09 2.21 (0.87 to 5.64) 7.39 .09 1.25 (0.56 to 2.80) 5.81 .59
III 2.29 (1.27 to 4.10) 3.00 .01 3.00 (1.22 to 7.43) 3.00 .02 1.71 (0.80 to 3.69) 3.00 .17
IV 1.29 (0.48 to 3.44) 0.005 .61 2.28 (0.66 to 7.90) 1.19 .06 0.42 (0.05 to 3.47) 0.12 .43
Postoperative
CA19-9, No.
265 131 134
1.00 (1.00 to 1.00) 22.21 <.001 1.00 (1.00 to 1.00) 14.67 <.001 1.00 (1.00 to 1.00) 14.29 <.001
Maximum tumor size, No. 342 165 177
1.00 (0.99 to 1.01) 2.66 .10 1.01 (0.99 to 1.01) 1.69 .19 1.00 (0.99 to 1.01) 0.64 .42
Differentiation status, No. 355 171 184
Well 1 (Referent) 1 (Referent) 1 (Referent)
Moderate 1.05 (0.67 to 1.65) 2.98 .83 1.03 (0.51 to 2.05) 0.08 .93 1.06 (0.58 to 1.93) 5.22 .85
Poor 1.31 (0.81 to 2.12) 2.00 .27 1.08 (0.52 to 2.24) 2.00 .83 1.60 (0.84 to 3.06) 2.00 .15
CatD expression, No. 362 174 188
Low 1 (Referent) 1 (Referent) 1 (Referent)
High 1.34 (1.00 to 1.77) 3.98 .04 1.22 (0.86 to 1.75) 1.25 .26 1.66 (0.97 to 2.84) 3.51 .05
*CatD ¼ cathepsin D; CI ¼ confidence interval; HR ¼ hazard ratio.
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Figure 2. Association of CatD expression with overall survival in resected PDAC patients in multivariable analysis and in an independent validation cohort. A)
Multivariable Cox proportional hazard regression analysis for overall survival stratified for gemcitabine treatment with CatD expression as one of the covariates along
with resection margin, smoking status, lymph node invasion, and local invasion status as other independent covariates. B) Multivariable Cox proportional hazard re-
gression analysis for overall survival stratified for 5FU/FA treatment arm with CatD expression as one of the covariates along with sex, smoking status, lymph node in-
vasion, and local invasion status as other independent covariates. C) CONSORT diagram of an independent validation cohort. D) Box and whisker plots predicting
observed survival time (blue) and predicted survival time (red) from the Cox proportional hazard model of ESPAC-Tplus cohort for the validation cohort stratified for
low and high CatD expression. Connecting lines depict the connection of the event in observed survival time and predicted survival time. E) Survival curves split by
CatD expression levels (high ¼ median H score > 22.35; low ¼ mean H score  22.35) in the validation cohort (univariate analysis). F) Multivariable Cox proportional
hazard regression analysis for overall survival stratified for validation cohort with CatD expression as one of the covariates along with sex, lymph node invasion, and
local invasion status as other independent covariates. All statistical tests were log-rank analyses using two-sided v2 tests. P< .05 considered statistically significant.
5FU/FA ¼ 5-fluorouracil/folinic acid; CatD ¼ cathepsin D; CI = confidence interval; CONSORT = Consolidated Standards of Reporting Trials; ESPAC = European Study
Group for Pancreatic Cancer; FOLFIRINOX ¼ folic acid, 5-fluorouracil, irinotecan, oxaliplatin; FFPE ¼ formalin-fixed paraffin-embedded; HR ¼ hazard ratio; m(st) ¼ me-
dian survival time in months; PDAC = pancreatic ductal carcinoma; PH = proportional hazard; RCT ¼ radiochemotherapy; TMA ¼ tissue microarray.
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confirmed our findings by measuring CatD, caspase 3, caspase
8, caspase 9, and ASMase activity in gemcitabine-resistant and
5FU-resistant cell lines. CatD activity was statistically signifi-
cantly increased, whereas caspase 3 and ASMase activities were
decreased in gemcitabine-resistant cell lines when compared to
controls and 5FU-resistant cell lines (Figure 3, B–D;
Supplementary Figure 10, available online).
To validate our claims, we used gemcitabine-resistant cell
line PaTu-8988T and silenced CatD by small interfering RNA
(small interfering CatD). Treatment with gemcitabine (1mM) in
CatD-silenced cells resulted in an increase in ASMase activity.
In parallel, we detected an increase in the rate of apoptosis,
measured by caspase 3 activity, whereas gemcitabine treatment
alone did not result in a statistically significant increase in cas-
pase 3 activity (Figure 3, E–G). Furthermore, silencing of CatD in
combination with gemcitabine treatment in gemcitabine-
resistant cell lines resulted in a significant decrease in prolifera-
tion after 48 hours (Figure 3H). In summary, in a crosstalk be-
tween CatD and ASMase, the silencing of CatD in gemcitabine-
resistant cell lines renders the cells responsive to gemcitabine
treatment.
Discussion
For this study, we included only patients treated in the
ESPAC-1 and ESPAC-3 trials studying the role of adjuvant che-
motherapy in pancreatic cancer. With this approach, we
aimed for a reduced bias by recruiting a stage-corrected group
of patients receiving mono-hemotherapy within a randomized
trial to test expression levels of a single biomarker, CatD, in
tissues harvested under standardized conditions and exter-
nally monitored, quality controlled clinical data. Furthermore,
utmost care was taken in generating the tissue microarray to
reduce bias of tumor heterogeneity as well as increasing sen-
sitivity and specificity of labeling. The bias of nonrandomized
studies precludes separating a predictive therapy–specific ef-
fect from a disease prognosis–specific effect. Using patients
from retrospective uncontrolled cohorts may have contributed
to the variability of previously published studies on the role
of CatD (17). Here, we demonstrate the prognostic capacity of
CatD expression levels for overall survival in resected PDAC
and its potential to predict the efficacy of adjuvant gemcita-
bine. We could not delineate a correlation between 5FU treat-
ment and CatD expression. However, different prognostic
markers (eg, dihydropyridine dehydrogenase) known to be in-
volved could be used in a combinatorial approach to stratify
patients (29). These data were confirmed in an independent
validation cohort with a prespecified outcome on which sam-
ple size calculation was based. Results from both cohorts im-
ply that adjuvant gemcitabine monotherapy might not be
considered in patients with high tumor cell CatD expression.
Because adjuvant gemcitabine-treated patients with low CatD
levels display a survival benefit, low CatD can be an effective
predictive marker of efficacy of gemcitabine. Furthermore,
in vitro high CatD expression reflected gemcitabine
resistance.
Mechanistically, the crosstalk between CatD and ASMase
confers resistance to gemcitabine, and if confirmed in a pro-
spective, randomized trial, CatD can be used as either a bio-
marker in the setting of precision medicine or as a novel drug
target for the treatment of pancreatic cancer.
The association of high CatD expression with poor survival
is in agreement with previous studies in node-negative breast
cancer patients that showed high tumor CatD expression also
Table 3. Multivariable analysis of CatD with overall survival factors*
Covariates
ESPAC-Tplus cohort Validation cohort
5FU/FA (n¼158) Gemcitabine (n¼ 167) Gemcitabine (n¼ 63)
HR (95% CI) z stat P HR (95% CI) z stat P HR (95% CI) z stat P
Resection margin
Negative 1.00 (Referent) 1.00 (Referent) 1.00 (Referent)
Positive 1.62 (1.13 to 2.33) 2.65 .007 1.27 (0.89 to 1.80) 1.36 .17 0.98 (0.39 to 2.42) –0.03 .97
Smoking status
Never 1.00 (Referent) 1.00 (Referent) —
Past 0.87 (0.58 to 1.29) –0.66 .50 1.24 (0.86 to 1.85) 1.14 .22 — — —
Present 0.96 (0.58 to 1.59) –0.12 .89 1.66 (1.05 to 2.72) 2.11 .03 — — —
Lymph node status
Negative 1.00 (Referent) 1.00 (Referent) 1.00 (Referent)
Positive 2.21 (1.33 to 3.65) 3.08 .002 1.63 (1.04 to 2.56) 2.14 .03 1.28 (0.58 to 2.82) 0.63 .52
Local invasion
Negative 1.00 (Referent) 1.00 (Referent) 1.00 (Referent)
Positive 1.41 (0.98 to 2.02) 1.89 .05 1.49 (1.04 to 2.13) 2.21 .02 1.41 (0.69 to 2.89) 1.02 .34
CatD expression
Low 1.00 (Referent) 1.00 (Referent) 1.00 (Referent)
High 1.04 (0.71 to 1.52) 0.21 .82 2.04 (1.10 to 3.76) 2.33 .02 3.38 (1.36 to 8.38) 2.60 .008
C statistic 0.62 6 0.02 0.62 6 0.02 0.64 6 0.05
AIC 1089.96 1198.06 242.42
Likelihood ratio test 25.79 (P < .001) 21.40 (P ¼ .002) 9.14 (P ¼ .06)
Comparison with model
leaving the CatD
expression
v2 ¼ 0.04, P ¼ .82 v2 ¼ 6.16, P ¼ .01 v2 ¼ 8.28, P ¼ .003
*AIC ¼ Akaike information criteria; CatD ¼ cathepsin D; CI ¼ confidence interval; ESPAC ¼ European Study Group for Pancreatic Cancer; HR ¼ hazard ratio.
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negatively correlated with survival (12,13,15,30). The one previ-
ously published study in which CatD expression in PDAC was
explored for possible correlation with metastasis involved
21 patients and showed 81% patients with CatD expression (14).
Our study reduces the ambiguity derived from studies that
Figure 3. Influence of CatD expression and activity in gemcitabine- and 5FU-resistant cell lines. A) Immunoblotting of protein lysates harvested from control, 5FU-resis-
tant and gemcitabine-resistant cell lines for CatD, caspase 3, and ASMase. GAPDH served as loading control. B–D) Fluorogenic activity measurement of CatD (B), cas-
pase 3 (C), and ASMase (D) in control, 5FU-resistant, and gemcitabine-resistant cell lines, L3.6pl, PaTu-8988T, and BxPC3. Data represented as fold changes compared to
control. E–G) Fluorogenic activity measurement of CatD (E), caspase 3 (F), and ASMase (G) on CatD silencing and gemcitabine treatment in gemcitabine-resistant cell
line, PaTu-8988T. Data represented as fold changes compared to control. H) MTT proliferation assay 48 hours after CatD silencing and gemcitabine treatment in gemci-
tabine-resistant cell lines. Data represented as percentage change compared to control. All the data are presented as box and whisker plots. P< .05 considered statisti-
cally significant vs respective controls. 5FU ¼ 5-fluorouracil; ASMase ¼ acid sphingomyelinase; CatD ¼ cathepsin D; GAPDH = gylceraldehyde 3-phosphate
dehydrogenase; Gem = gemcitabine; si = small interfering.
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found either prometastatic or antitumorigenic effects associ-
ated with CatD expression (9,14,31,32).
In addition to associations with survival outcomes, our
study detected an association between CatD expression and
gemcitabine responsiveness. One potential explanation regard-
ing how increased CatD expression can influence gemcitabine
responsiveness is the crosstalk of CatD with ASMase and cer-
amide. The balance between bioactive sphingolipids, ceramides,
sphingosine, and sphingosine-1-phosphate functions as a bio-
stat with profound effects on cell death, growth, and differentia-
tion (33). It has been shown that ASMase-derived ceramide
specifically binds to, and thereby induces, the proteolytic activ-
ity of CatD within the endolysosomal compartments (caspase 3
activation; see Figure 3, C and G) (27,34–36). Drug-resistant cells
maintain low ceramide levels by increasing sphingomyelin syn-
thesis or by preventing sphingomyelin breakdown (26). Our data
suggest that the ceramide–ASMase–CatD axis regulates intracel-
lular ceramide levels by an autocrine loop with reciprocal
effects on CatD expression and ASMase activity, and failure of it
results in gemcitabine resistance (37).
An obvious drawback of our study is the lack of 5FU-treated
patients in our validation cohort. 5FU is not regularly used in
clinical care in the adjuvant setting in Germany and not recom-
mended in the German treatment guidelines since the publica-
tion of the CONKO-001 study (38) and cross-comparison of
efficacy and side effects with the ESPAC-3 data. Currently,
FOLFIRINOX (folic acid, 5-fluorouracil, irinotecan, oxaliplatin)
would be preferred over a gemcitabine-based regime with re-
spect to the progression-free survival and overall survival data
(PRODIGE 24/CCTG PA.6) at the expense of severe adverse
effects (39), whereas adjuvant nab-paclitaxel plus gemcitabine
did not show improved progression-free survival compared to
gemcitabine alone (40). For less-fit patients, gemcitabine plus
capecitabine is a treatment of choice (5). Monotherapy with
gemcitabine alone is another reasonable option considering its
lower toxicity profile, particularly for patients with a borderline
performance status or a comorbidity profile that precludes
multi-agent therapy (41,42). Furthermore, the COMPASS (43)
trial revealed a gemcitabine-based signature to be equally po-
tent in comparison to a platin-based signature, and thus it is
still undecided what treatment would be best.
The data presented here comprise the largest and most com-
prehensive analysis of a prognostic role of CatD on patient sur-
vival and support a prognostic as well as predictive role of CatD
with regard to therapy response. We believe, subject to prospec-
tive validation, in patients with low CatD expression adjuvant
treatment with a gemcitabine-backbone therapeutic regimen
can be employed, but for patients with high CatD expression, a
nongemcitabine regimen such as FOLFORINOX might be of
greater benefit. This study could therefore pave the way for in-
troducing CatD expression into the treatment stratification of
pancreatic cancer patients provided that randomized, prospec-
tive studies can confirm its effectiveness as a biomarker.
Furthermore, owing to high expression of CatD in other solid
tumors, such as breast cancer and colorectal cancer, CatD can
be a predictive marker for therapeutic response in these
cancers.
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